semaglutide efficacy weight loss Zepbound vs. vs. Wegovy: What's the Difference? Weight loss results after 8

Zepbound (approved November 2023): for chronic weight management in obesity, or in overweight with a related condition, and since 2024 additionally for obstructive sleep apnoea

Some of the most common side effects include: Dizziness Fatigue Diarrhea Constipation Gassiness Headache Nausea Vomiting Distension If you experience any of these side effects, be sure to notify your provider promptly

FDA approval dates to 1959, making it one of the longest-studied weight-loss agents, though data on long-term safety beyond 12 weeks remains limited

The challenge is in making sure that everyone who needs these medications has access to them, regardless of the obstacles put in place by insurance companies

These are generally annual or semi-annual expenses rather than recurring monthly costs

This approval is meaningful because it enables us to provide a new treatment option that reflects Novo Nordisks continued innovation in diabetes care. Related articles Novos Sogroya gets Korea reimbursement for growth hormone deficiency Hanmi starts phase 3 diabetes trial for GLP-1 drug ahead of obesity launch Korea finds illegal sales in GLP-1 obesity drug inspections Korea begins insurance coverage for Novo Nordisks weekly growth hormone drug Korea may ease GLP-1 drug rules as Novos Ozempic faces access limits: diabetes association In Korea, Lilly and Novo Nordisk soar on obesity drug boom as Pfizer, MSD retreat [Column] Innovative diabetes drugs still out of reach for patients who need them most Can Samsungs Galaxy Watch help GLP1 patients keep muscle and be worth paying for